A new trading data show Aurinia Pharmaceuticals Inc. (AUPH) is showing positive returns.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) stock fell -0.97% on Tuesday to $8.21 against a previous-day closing price of $8.29. With 2.15 million shares changed hands, the volume of the stock remained lighter than its average volume of 3.1 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $8.75 whereas the lowest price it dropped to was $8.14. The 52-week range on AUPH shows that it touched its highest point at $20.48 and its lowest point at $4.07 during that stretch. It currently has a 1-year price target of $12.50. Beta for the stock currently stands at 0.92.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AUPH was down-trending over the past week, with a drop of -4.98%, but this was up by 78.48% over a month. Three-month performance surged to 15.63% while six-month performance fell -21.81%. The stock lost -49.51% in the past year, while it has gained 90.05% so far this year. A look at the trailing 12-month EPS for AUPH yields -0.83 with Next year EPS estimates of -0.88. For the next quarter, that number is -0.28. This implies an EPS growth rate of -61.40% for this year and -3.50% for next year.

Float and Shares Shorts:

At present, 141.86 million AUPH shares are outstanding with a float of 132.88 million shares on hand for trading. On Dec 29, 2022, short shares totaled 7.56 million, which was 5.32% higher than short shares on Nov 29, 2022. In addition to Mr. Peter S. Greenleaf M.B.A. as the firm’s Pres, CEO & Director, Mr. Joseph M. Miller CPA serves as its Chief Financial Officer.

Institutional Ownership:

Through their ownership of 41.94% of AUPH’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 29.57% of AUPH, in contrast to 10.04% held by mutual funds. Shares owned by individuals account for 0.40%. As the largest shareholder in AUPH with 5.52% of the stake, Deep Track Capital LP holds 7,841,570 shares worth 7,841,570. A second-largest stockholder of AUPH, BlackRock Fund Advisors, holds 6,515,058 shares, controlling over 4.59% of the firm’s shares. Fidelity Management & Research Co is the third largest shareholder in AUPH, holding 3,732,577 shares or 2.63% stake. With a 2.12% stake in AUPH, the iShares Russell 2000 ETF is the largest stakeholder. A total of 3,008,566 shares are owned by the mutual fund manager. The iShares Russell 2000 Growth ETF, which owns about 0.79% of AUPH stock, is the second-largest Mutual Fund holder. It holds 1,122,074 shares valued at 4.85 million. iShares Biotechnology ETF holds 0.76% of the stake in AUPH, owning 1,083,406 shares worth 4.68 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Sep 29, 2022, AUPH reported revenue of $28.19M and operating income of -$35.99M. The EBITDA in the recently reported quarter was -$35.15M and diluted EPS was -$0.25.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AUPH since 8 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With AUPH analysts setting a high price target of $15.00 and a low target of $5.18, the average target price over the next 12 months is $11.59. Based on these targets, AUPH could surge 82.7% to reach the target high and fall by -36.91% to reach the target low. Reaching the average price target will result in a growth of 41.17% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. AUPH will report FY 2022 earnings on 02/26/2024. Analysts have provided yearly estimates in a range of -$0.83 being high and -$0.91 being low. For AUPH, this leads to a yearly average estimate of -$0.85. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Aurinia Pharmaceuticals Inc. surprised analysts by $0.17 when it reported -$0.06 EPS against a consensus estimate of -$0.23. The surprise factor in the prior quarter was -$0.03. Based on analyst estimates, the high estimate for the next quarter is -$0.25 and the low estimate is -$0.33. The average estimate for the next quarter is thus -$0.28.

Leave a Comment

Your email address will not be published. Required fields are marked *